New Horizons: Is Obesity a Disorder of Neurotransmission?

被引:10
|
作者
Caron, Alexandre [1 ,2 ,3 ]
Michael, Natalie Jane [1 ,2 ]
机构
[1] Univ Laval, Fac Pharm, Quebec City, PQ, Canada
[2] Quebec Heart & Lung Inst, Quebec City, PQ, Canada
[3] Montreal Diabet Res Ctr, Montreal, PQ, Canada
来源
关键词
obesity; neurotransmitters; melanocortin; neurometabolic pharmacology; antipsychotics; AGOUTI-RELATED PROTEIN; NEURONS REGULATE ENERGY; HYPOTHALAMIC PROOPIOMELANOCORTIN NEURONS; RECEPTOR-DEFICIENT MICE; DIET-INDUCED OBESITY; RAT ARCUATE NUCLEUS; INDUCED WEIGHT-GAIN; NEUROPEPTIDE-Y; FOOD-INTAKE; POMC NEURONS;
D O I
10.1210/clinem/dgab421
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obesity is a disease of the nervous system. While some will view this statement as provocative, others will take it as obvious. Whatever our side is, the pharmacology tells us that targeting the nervous system works for promoting weight loss. It works, but at what cost? Is the nervous system a safe target for sustainable treatment of obesity? What have we learned-and unlearned-about the central control of energy balance in the last few years? Herein we provide a thought-provoking exploration of obesity as a disorder of neurotransmission. We discuss the state of knowledge on the brain pathways regulating energy homeostasis that are commonly targeted in anti-obesity therapy and explore how medications affecting neurotransmission such as atypical antipsychotics, antidepressants, and antihistamines relate to body weight. Our goal is to provide the endocrine community with a conceptual framework that will help expending our understanding of the pathophysiology of obesity, a disease of the nervous system.
引用
收藏
页码:E4872 / E4886
页数:15
相关论文
共 50 条
  • [1] Fighting with obesity: the "gold standard" and new horizons
    Drapkina, O. M.
    Dubolazova, Yu V.
    Boytsov, S. A.
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2016, 12 (04) : 450 - 458
  • [2] Horizons in the Pharmacotherapy of Obesity
    Arch J.R.
    [J]. Current Obesity Reports, 2015, 4 (4) : 451 - 459
  • [3] New Horizons: Epidemiology of Obesity, Diabetes Mellitus, and Cancer Prognosis
    Harborg, Sixten
    Kjaergaard, Kasper A.
    Thomsen, Reimar Wernich
    Borgquist, Signe
    Cronin-Fenton, Deirdre
    Hjorth, Cathrine F.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (04): : 924 - 935
  • [4] BRAIN NEUROTRANSMISSION IN PANIC DISORDER
    ERIKSSON, E
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1987, 76 : 31 - 37
  • [5] New Horizons in the Treatment of Age-Associated Obesity, Sarcopenia and Osteoporosis
    Alexander Kalinkovich
    Maria Becker
    Gregory Livshits
    [J]. Drugs & Aging, 2022, 39 : 673 - 683
  • [6] New Horizons in the Treatment of Age-Associated Obesity, Sarcopenia and Osteoporosis
    Kalinkovich, Alexander
    Becker, Maria
    Livshits, Gregory
    [J]. DRUGS & AGING, 2022, 39 (09) : 673 - 683
  • [7] Determinants, Screening, Prevention and Management of Obesity in Youth: New Evidence and Horizons
    Androutsos, Odysseas
    Charmandari, Evangelia
    [J]. NUTRIENTS, 2022, 14 (16)
  • [8] Eating and Obesity-The New World Disorder
    Rigby, Neville
    [J]. NUTRIENTS, 2013, 5 (10): : 4206 - 4210
  • [9] New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications
    Garvey, W. Timothy
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (04): : E1339 - E1347
  • [10] Translational research into gut microbiota: new horizons on obesity treatment: updated 2014
    Tsukumo, Daniela M.
    Carvalho, Bruno M.
    Carvalho-Filho, Marco A.
    Saad, Mario J. A.
    [J]. ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2015, 59 (02): : 154 - 160